Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Sagent Pharmaceuticals Announces The Launch Of Ondansetron Injection, USP

https://static.seekingalpha.com/uploads/2012/9/10/saupload_sgnt.jpg

SCHAUMBURG, Ill., Sept. 10, 2012 (CRWENewswire) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ondansetron Injection, USP, an antiemetic, in two latex-free vial presentations. According to IMS, for the 12 months ending June 2012, the US market for Ondansetron Injection, USP approximated $49 million. As with all products in Sagent's portfolio, Ondansetron features the company's PreventIV Measures(NYSE:SM) packaging and labeling, designed to help reduce medication errors.

About Ondansetron Injection, USP

Ondansetron Injection, USP is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and for prevention of postoperative nausea and/or vomiting.

The package insert, available at www.sagentpharma.com, contains the indications, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT:

INVESTOR CONTACT:
Jonathon Singer, Sagent
847-908-1605

Source: Sagent Pharmaceuticals, Inc.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

www.crwenewswire.com/150136/press-releas.../

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.